Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China – Tasly obtains exclusive development and commercialization rights for STRO-002 for Greater China – – License includes a $40 million...